1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Tri-path

Anonymous board for Tri-path

Sort By:
Title
Replies Views
Last Message ↓
  1. Anonymous
    Replies:
    49
    Views:
    23,115
  2. Anonymous
    Replies:
    3
    Views:
    4,176
  3. Anonymous
    Replies:
    1
    Views:
    2,264
  4. Anonymous
    Replies:
    7
    Views:
    2,786
  5. Anonymous
    Replies:
    3
    Views:
    2,505
  6. Anonymous
    Replies:
    4
    Views:
    4,753
  7. Anonymous
    Replies:
    24
    Views:
    8,107
  8. Anonymous
    Replies:
    9
    Views:
    3,161
  9. Anonymous
    Replies:
    26
    Views:
    9,498
  10. Anonymous
    Replies:
    4
    Views:
    3,136
  11. Anonymous
    Replies:
    14
    Views:
    3,649
  12. Anonymous
    Replies:
    60
    Views:
    15,025
  13. Anonymous
    Replies:
    14
    Views:
    6,776
  14. Anonymous
    Replies:
    17
    Views:
    8,147
  15. Anonymous
    Replies:
    2
    Views:
    3,897

Thread Display Options

Loading...